Clinical trial · Interventional
Microwave Ablation in the Treatment of Stage I Non Small Cell Lung Cancer
NCT02896166CI-TRIAL-00028123unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Lung cancer, the leading cause of cancer related mortality. Among them, non small cell lung cancer accounts for 85%. Only part of patients could be treated with radical surgery, and some patients were unfit for surgery due to the poor cardio-pulmonary function or refuse surgery. For those patients, microwave ablation (MWA) could be an alternative treatment. Several small sample retrospective studies verified that MWA could be an efficacy and safe treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stage I NSCLC | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| microwave ablation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- microwave ablation
- description
- The procedure is performed similar to a needle biopsy of the lung, under CT guidance. Placement of the needle-electrode is similar to needle placement for CT-guided biopsy. Appropriate positioning of the microwave ablation antenna is confirmed by CT imaging.
- interventionNames
- Other: microwave ablation
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- From the date of randomization until the date of death from any cause，assessed up to 36 months
Secondary outcomes (1)
- measure
- Disease free survival
- timeFrame
- From the date of randomization until the date of first documented progression，assessed up to 36 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient has a histologically or cytologically verified NSCLC, 2. The tumors small enough to treat (usually \<4 cm), and without chest pleura invasion. 3. Clinical stage I NSCLC with no other sites of disease,. 4. Patient is not a candidate for surgical removal of the cancer, or refused surgery. 5. Patient is not a candidate for radiation therapy, or refused radiation therapy. 6. Patient has \> 6 month life expectancy. 7. Eastern Cooperative Oncology Group performance status of 0 to 2. 8. No prior anticancer treatments including surgery, radiation,chemotherapy or local treatments. 9. Sufficient organ functions. 10. Written informed consent. Exclusion Criteria: 1. Active bacterial or fungous infection. 2. Simultaneous or metachronous (within the past 5 years) double cancers. 3. Women during pregnancy or breast-feeding. 4. Interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema. 5. Uncontrollable diabetes mellitus. 6. History of severe heart disease, heart failure, myocardial infarction within the past 6 months or attack of angina pectoris within the past 6 months.
References
Publications (0)
Data not yet available
No reference posted for this study.